Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure

被引:55
作者
Funayama, H [1 ]
Nakamura, T [1 ]
Saito, T [1 ]
Yoshimura, A [1 ]
Saito, M [1 ]
Kawakami, M [1 ]
Ishikawa, S [1 ]
机构
[1] Jichi Med Sch, Omiya Med Ctr, Dept Med, Omikya Ku, Saitama 3308503, Japan
关键词
impaired water excretion; cardiac dysfunction; baroreceptors;
D O I
10.1111/j.1523-1755.2004.00902.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Impaired water excretion occurs in patients with congestive heart failure. The present study was undertaken to determine whether urinary excretion of aquaporin-2 (AQP-2) water channel is exaggerated in patients with congestive heart failure dependent upon arginine vasopressin (AVP). Methods. Sixty-five patients with congestive heart failure and eight age- and gender-matched control subjects were examined. The patients were divided into four groups according to the criteria of New York Heart Association (NYHA). Plasma AVP levels, urinary excretion of AQP-2, and cardiac index were determined. Results. Plasma AVP levels were progressively increased following the severity of NYHA class in the patients with congestive heart failure. Cardiac index was inversely decreased, and there was a negative correlation between plasma AVP levels and cardiac index (r=0.430, P<0.02). Urinary excretion of AQP-2 was 187.3 +/- 50.2 fmol/mg creatinine in the control subjects. It was markedly increased in the patients. Urinary excretion of AQP-2 was elevated to 1144.4 +/- 257.5 and 990.5 +/- 176.0 fmol/mg creatinine in the patients with NYHA class III and class IV, respectively, values significantly greater than the control subjects (P<0.05). Urinary excretion of AQP-2 had a positive correlation with plasma AVP levels (r=0.280, <0.02). Conclusion. The present study indicates that exaggerated urinary excretion of AQP-2 is dependent on baroreceptor-mediated release of AVP in patients with congestive heart failure.
引用
收藏
页码:1387 / 1392
页数:6
相关论文
共 35 条
[31]   RADIOIMMUNOASSAY OF PLASMA ARGININE VASOPRESSIN IN HYPONATREMIC PATIENTS WITH CONGESTIVE HEART-FAILURE [J].
SZATALOWICZ, VL ;
ARNOLD, PE ;
CHAIMOVITZ, C ;
BICHET, D ;
BERL, T ;
SCHRIER, RW .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (05) :263-266
[32]   Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure [J].
Udelson, JE ;
Smith, WB ;
Hendrix, GH ;
Painchaud, CA ;
Ghazzi, M ;
Thomas, I ;
Ghali, JK ;
Selaru, P ;
Chanoine, F ;
Pressler, ML ;
Konstam, MA .
CIRCULATION, 2001, 104 (20) :2417-2423
[33]   Comparison of three methods to quantify urinary aquaporin-2 protein [J].
Umenishi, F ;
Summer, SN ;
Cadnapaphornchai, M ;
Schrier, RW .
KIDNEY INTERNATIONAL, 2002, 62 (06) :2288-2293
[34]   Upregulation of aquaporin-2 water channel expression in chronic heart failure rat [J].
Xu, DL ;
Martin, PY ;
Ohara, M ;
StJohn, J ;
Pattison, T ;
Meng, XZ ;
Morris, K ;
Kim, JK ;
Schrier, RW .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1500-1505
[35]   VASOPRESSIN INCREASES AQP-CD WATER CHANNEL IN APICAL MEMBRANE OF COLLECTING DUCT CELLS IN BRATTLEBORO RATS [J].
YAMAMOTO, T ;
SASAKI, S ;
FUSHIMI, K ;
ISHIBASHI, K ;
YAOITA, E ;
KAWASAKI, K ;
MARUMO, F ;
KIHARA, I .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1995, 268 (06) :C1546-C1551